TY - JOUR
PY - 2022//
TI - Suicidality and quality of life in treatment-resistant depression patients in Latin America: secondary interim analysis of the TRIAL Study
JO - Frontiers in psychiatry
A1 - Corral, Ricardo
A1 - Alessandria, Hernan
A1 - Agudelo Baena, Lina María
A1 - Ferro, Eugenio
A1 - Duque, Xochitl
A1 - Quarantini, Lucas
A1 - Caldieraro, Marco Antonio
A1 - Cabrera, Patricia
A1 - Kanevsky, Gabriela
SP - e812938
EP - e812938
VL - 13
IS -
N2 - BACKGROUND: A large proportion of patients with major depressive disorder (MDD) have treatment-resistant depression (TRD). The TRAL study examines the impact of TRD on suicidality and health-related quality of life (HRQoL) among MDD patients in 4 Latin American countries.
METHODS: In this multicenter, prospective, observational study, MDD patients were recruited from 33 sites in Mexico, Colombia, Brazil, and Argentina. Patients were assessed for TRD, defined as failure to respond to ≥2 antidepressant medications of adequate dose and duration. Other assessments included current disease status, Mini International Neuropsychiatric Interview (MINI), Columbia-Suicide Severity Rating Scale (C-SSRS), 5 Level EQ-5D (EQ-5D-5L), Patient Health Questionnaire-9 (PHQ-9), and Sheehan Disability Scale (SDS).
RESULTS: 1,475 MDD patients were included in the analysis (mean age, 45.6 years; 78% women), and 429 met criteria for TRD. Thoughts of suicide and suicide attempts were more common among TRD patients (38.7%) compared with non-TRD patients (24.9%; P < 0.0001), according to the current disease status questionnaire. The C-SSRS showed that lifetime suicidal behavior was significantly more common among TRD patients than non-TRD patients (13.8 vs. 10.0%; P = 0.0384). Compared with non-TRD patients, TRD patients showed significantly greater adverse impacts on QoL (EQ-5D-5L), more severe depression (PHQ-9), and greater functional impairment (SDS).
CONCLUSION: TRD patients in clinical sites from Mexico, Colombia, Brazil, and Argentina were more likely to experience suicidality and negative effects on HRQoL than non-TRD patients.
Language: en
LA - en SN - 1664-0640 UR - http://dx.doi.org/10.3389/fpsyt.2022.812938 ID - ref1 ER -